Dr. Lonial on Encouraging Data With Emerging Agents in Myeloma

Sagar Lonial, MD
Published: Friday, Apr 05, 2019



Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in the myeloma treatment paradigm.

As a single agent, selinexor has shown response rates of approximately 20% to 25%. The median progression-free survival (PFS) with the XPO1 (CRM1) inhibitor is approximately 2.5 to 3.0 months. Even if patients don’t achieve an objective response, they may experience stable disease for a significant amount of time. However, this drug is not without toxicity, with common adverse events such as nausea, vomiting, weight loss, and thrombocytopenia, Lonial notes.

Venetoclax (Venclexta), an agent that has made headway in chronic lymphocytic leukemia, acute lymphocytic leukemia, and lymphoma, appears to be effective in myeloma as well. The BCL-2 inhibitor is a well-tolerated drug with a response rate of about 40% in patients with translocation 11;14. Notably, response rates have jumped to approximately 65% in combination with dexamethasone, and even higher in combination with other commonly used agents in this space.

Additionally, CAR T-cell therapy has shown response rates in the 80% to 90% range. Though, it has been a challenge getting patients enrolled on these trials, Lonial says. One also has to keep in mind the strict selection criteria for these studies. With bb2121, the remission duration in the initial trial was about 11 months. The field is waiting for longer-term follow-up data and PFS results from the phase II KarMMa study (NCT03361748).
SELECTED
LANGUAGE


Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in the myeloma treatment paradigm.

As a single agent, selinexor has shown response rates of approximately 20% to 25%. The median progression-free survival (PFS) with the XPO1 (CRM1) inhibitor is approximately 2.5 to 3.0 months. Even if patients don’t achieve an objective response, they may experience stable disease for a significant amount of time. However, this drug is not without toxicity, with common adverse events such as nausea, vomiting, weight loss, and thrombocytopenia, Lonial notes.

Venetoclax (Venclexta), an agent that has made headway in chronic lymphocytic leukemia, acute lymphocytic leukemia, and lymphoma, appears to be effective in myeloma as well. The BCL-2 inhibitor is a well-tolerated drug with a response rate of about 40% in patients with translocation 11;14. Notably, response rates have jumped to approximately 65% in combination with dexamethasone, and even higher in combination with other commonly used agents in this space.

Additionally, CAR T-cell therapy has shown response rates in the 80% to 90% range. Though, it has been a challenge getting patients enrolled on these trials, Lonial says. One also has to keep in mind the strict selection criteria for these studies. With bb2121, the remission duration in the initial trial was about 11 months. The field is waiting for longer-term follow-up data and PFS results from the phase II KarMMa study (NCT03361748).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x